After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

As well as part of the Global Regulatory Affairs & Safety leadership, Alan is also key member of Amgen's cross-functional European and other international management teams, which set and guide the ...

CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Wall Street drifted higher as gains for most stocks outweighed drops for Alphabet and some other big-name companies following their latest profit reports ...

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

(Reuters) - President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from ...